News summarySEC EDGARNov 16, 2026, 12:00 PM
Summit Therapeutics 8-K (8.01, 9.01): other events
Summit Therapeutics said the FDA issued a Complete Response Letter rejecting ivonescimab’s BLA in its current form, citing lack of statistically significant overall-survival improvement; the HARMONi trial met its progression-free-survival endpoint.